The GLP-1 Dilemma: Medical Breakthrough Meets Financial Reality
Penn LDITopic alignment 88
A University of Pennsylvania panel of experts highlighted an unusual dilemma facing the American health care system: GLP-1 medications are highly effective treatments for obesity and several related chronic conditions, and their prices have fallen substantially, but the enormous number of potential patients makes broad insurance coverage financially challenging. Coming together for an Oct. 23 […]
Filed under
- GLP-1 cost managementmatch 88
How to measure the long-term value of GLP-1s within employer healthcare costs
HFMATopic alignment 92
Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes
USC SchaefferTopic alignment 95
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
MedCity NewsTopic alignment 86
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
Endpoints NewsTopic alignment 86